Figure 1.
Immune monitoring. (A) Effects of mesenchymal stem cells (MSCs) on cPRA. Change in Calculated Panel Reactive Antibody (cPRA) assay from day 1 to 6 months demonstrates that only one subject in the 20-million (M) arm had a moderate donor-specific cPRA reaction and no subjects in the 100M and the 200M group had any reaction. (B) Effects of MSCs on early T cell activation. Change in T cells expression of early activation marker CD69 demonstrates that allo-hMSCs in all treatment arms suppresses early T cell activation. (C) Effects of MSCs of late/chronic T cell activation. Change in T cells expression of late/chronic activation marker CD25 demonstrates that allo-hMSCs in all treatment arms did not induce late/chronic T cell activation and the 20 million dose significantly suppressed activation (*p = .03) at 6 mo as compared to baseline.